EGFR as a prognostic biomarker and therapeutic target in ovarian cancer

Evaluation of patient cohort and literature review

Christine Mehner, Ann L Oberg, Krista M. Goergen, Kimberly R. Kalli, Matthew J. Maurer, Aziza Nassar, Ellen L Goode, Gary Keeney, Aminah Jatoi, Derek C Radisky, Evette S Radisky

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Background: Limited effectiveness of therapeutic agents targeting epidermal growth factor receptor (EGFR) in clinical trials using unselected ovarian cancer patients has prompted efforts to more effectively stratify patients who might best benefit from these therapies. A series of studies that have evaluated immunohistochemical (IHC) staining of EGFR in ovarian cancer biopsies has produced unclear results as to the utility of this measure as a prognostic biomarker. Here, we used one of the largest, single institution cohorts to date to determine possible associations of EGFR expression with patient outcome. Methods: We performed IHC staining of EGFR in tissue microarrays including nearly 500 patient tumor samples. Staining was classified by subcellular localization (membranous, cytoplasmic) or by automated image analysis algorithms. We also performed a literature review to place these results in the context of previous studies. Results: No significant associations were found between EGFR subcellular localization or expression and histology, stage, grade, or outcome. These results were broadly consistent with the consensus of the reviewed literature. Conclusions: These results suggest that IHC staining for EGFR may not be a useful prognostic biomarker for ovarian cancer patients. Future studies should pursue other staining methods or analysis in combination with other pathway mediators.

Original languageEnglish (US)
Pages (from-to)589-599
Number of pages11
JournalGenes and Cancer
Volume8
Issue number5-6
DOIs
StatePublished - May 1 2017

Fingerprint

Epidermal Growth Factor Receptor
Ovarian Neoplasms
Biomarkers
Staining and Labeling
Therapeutics
Histology
Clinical Trials
Biopsy
Neoplasms

Keywords

  • EGFR
  • Epidermal growth factor receptor
  • Ovarian cancer
  • Prognostic biomarker
  • Tissue microarray

ASJC Scopus subject areas

  • Genetics
  • Cancer Research

Cite this

EGFR as a prognostic biomarker and therapeutic target in ovarian cancer : Evaluation of patient cohort and literature review. / Mehner, Christine; Oberg, Ann L; Goergen, Krista M.; Kalli, Kimberly R.; Maurer, Matthew J.; Nassar, Aziza; Goode, Ellen L; Keeney, Gary; Jatoi, Aminah; Radisky, Derek C; Radisky, Evette S.

In: Genes and Cancer, Vol. 8, No. 5-6, 01.05.2017, p. 589-599.

Research output: Contribution to journalReview article

@article{15d40e32e23b433ba7ae05deddf88fb4,
title = "EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: Evaluation of patient cohort and literature review",
abstract = "Background: Limited effectiveness of therapeutic agents targeting epidermal growth factor receptor (EGFR) in clinical trials using unselected ovarian cancer patients has prompted efforts to more effectively stratify patients who might best benefit from these therapies. A series of studies that have evaluated immunohistochemical (IHC) staining of EGFR in ovarian cancer biopsies has produced unclear results as to the utility of this measure as a prognostic biomarker. Here, we used one of the largest, single institution cohorts to date to determine possible associations of EGFR expression with patient outcome. Methods: We performed IHC staining of EGFR in tissue microarrays including nearly 500 patient tumor samples. Staining was classified by subcellular localization (membranous, cytoplasmic) or by automated image analysis algorithms. We also performed a literature review to place these results in the context of previous studies. Results: No significant associations were found between EGFR subcellular localization or expression and histology, stage, grade, or outcome. These results were broadly consistent with the consensus of the reviewed literature. Conclusions: These results suggest that IHC staining for EGFR may not be a useful prognostic biomarker for ovarian cancer patients. Future studies should pursue other staining methods or analysis in combination with other pathway mediators.",
keywords = "EGFR, Epidermal growth factor receptor, Ovarian cancer, Prognostic biomarker, Tissue microarray",
author = "Christine Mehner and Oberg, {Ann L} and Goergen, {Krista M.} and Kalli, {Kimberly R.} and Maurer, {Matthew J.} and Aziza Nassar and Goode, {Ellen L} and Gary Keeney and Aminah Jatoi and Radisky, {Derek C} and Radisky, {Evette S}",
year = "2017",
month = "5",
day = "1",
doi = "10.18632/genesandcancer.142",
language = "English (US)",
volume = "8",
pages = "589--599",
journal = "Genes and Cancer",
issn = "1947-6019",
publisher = "SAGE Publications Inc.",
number = "5-6",

}

TY - JOUR

T1 - EGFR as a prognostic biomarker and therapeutic target in ovarian cancer

T2 - Evaluation of patient cohort and literature review

AU - Mehner, Christine

AU - Oberg, Ann L

AU - Goergen, Krista M.

AU - Kalli, Kimberly R.

AU - Maurer, Matthew J.

AU - Nassar, Aziza

AU - Goode, Ellen L

AU - Keeney, Gary

AU - Jatoi, Aminah

AU - Radisky, Derek C

AU - Radisky, Evette S

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background: Limited effectiveness of therapeutic agents targeting epidermal growth factor receptor (EGFR) in clinical trials using unselected ovarian cancer patients has prompted efforts to more effectively stratify patients who might best benefit from these therapies. A series of studies that have evaluated immunohistochemical (IHC) staining of EGFR in ovarian cancer biopsies has produced unclear results as to the utility of this measure as a prognostic biomarker. Here, we used one of the largest, single institution cohorts to date to determine possible associations of EGFR expression with patient outcome. Methods: We performed IHC staining of EGFR in tissue microarrays including nearly 500 patient tumor samples. Staining was classified by subcellular localization (membranous, cytoplasmic) or by automated image analysis algorithms. We also performed a literature review to place these results in the context of previous studies. Results: No significant associations were found between EGFR subcellular localization or expression and histology, stage, grade, or outcome. These results were broadly consistent with the consensus of the reviewed literature. Conclusions: These results suggest that IHC staining for EGFR may not be a useful prognostic biomarker for ovarian cancer patients. Future studies should pursue other staining methods or analysis in combination with other pathway mediators.

AB - Background: Limited effectiveness of therapeutic agents targeting epidermal growth factor receptor (EGFR) in clinical trials using unselected ovarian cancer patients has prompted efforts to more effectively stratify patients who might best benefit from these therapies. A series of studies that have evaluated immunohistochemical (IHC) staining of EGFR in ovarian cancer biopsies has produced unclear results as to the utility of this measure as a prognostic biomarker. Here, we used one of the largest, single institution cohorts to date to determine possible associations of EGFR expression with patient outcome. Methods: We performed IHC staining of EGFR in tissue microarrays including nearly 500 patient tumor samples. Staining was classified by subcellular localization (membranous, cytoplasmic) or by automated image analysis algorithms. We also performed a literature review to place these results in the context of previous studies. Results: No significant associations were found between EGFR subcellular localization or expression and histology, stage, grade, or outcome. These results were broadly consistent with the consensus of the reviewed literature. Conclusions: These results suggest that IHC staining for EGFR may not be a useful prognostic biomarker for ovarian cancer patients. Future studies should pursue other staining methods or analysis in combination with other pathway mediators.

KW - EGFR

KW - Epidermal growth factor receptor

KW - Ovarian cancer

KW - Prognostic biomarker

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=85042944607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042944607&partnerID=8YFLogxK

U2 - 10.18632/genesandcancer.142

DO - 10.18632/genesandcancer.142

M3 - Review article

VL - 8

SP - 589

EP - 599

JO - Genes and Cancer

JF - Genes and Cancer

SN - 1947-6019

IS - 5-6

ER -